Clarity announced a supply deal for Actinium-225, which will be investigated as the radioactive payload for a new bisPSMA therapy.
There are high hopes in the industry for alpha emitters like Actinium, with a shorter but more destructive path length. Theoretically, this could be more selective and more destructive to targeted cells, but so far it has proven difficult to strike the balance.
Clarity’s double-pronged ligand has resulted responses at lower doses of radiation than competitors in early trials. The hope is a similar approach here will help harness the power of alpha particles with greater control over the risks.
Stepping back, this was a very welcome update, showing Clarity’s intention to strengthen its early stage pipeline and repeat its early success in new indications.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)